Promoting a Basic Understanding of Chemical Threats to Skin

Developing medical countermeasures to protect civilians against intentional and accidental toxic chemical exposure that can lead to mass casualties is a major goal of the biodefense program at NIH. More specifically, this goal is executed by the Chemical Countermeasures Research Program (CCRP) administered by NIAID and executed in partnership with several other ICs across the NIH, including NIAMS. (NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Chemical Threats). NIAMS has been a critical and active partner in this trans-NIH effort since the CCRP’s inception in 2006. In order to broaden its research base and raise the awareness of the scientific community at large about the urgent need for effective countermeasures against chemical threats, the CCRP is encouraging its IC partners to issue IC-specific Notices of Funding Opportunities (NOFOs) to further engage their respective research disciplines that are not currently engaged in the medical countermeasure research field. This initiative is a response to that request. The intent of the initiative is to encourage the NIAMS skin research community to contribute to the basic understanding of injuries caused by those toxic chemicals identified by the U.S. Department of Homeland Security as high consequence public health threats and to explore the local and systemic mechanisms of chemical wound development, healing, and long-term consequences.

Resources

NIAID Chemical Countermeasures Research Program

NINDS CounterACT

Current CCRP/CounterACT Funding Opportunities

• PAR-23-139: CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/ Developmental Research Projects (R21 Clinical Trial Not Allowed)
• PA-25-093: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
• PAR-25-114: CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/ Developmental Research Projects (R21 Clinical Trial Not Allowed)
• NOT-NS-24-126: Notice of Intent to Publish a Funding Opportunity Announcement for CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/ UH3 Clinical Trial Not Allowed)